# Metronomic chemotherapy
Metronomic chemotherapy is a way of giving cytotoxic cancer drugs continuously at low, largely non-toxic doses on a frequent schedule with no prolonged drug-free breaks, in contrast to conventional maximum-tolerated-dose (MTD) cycles separated by 2–3-week rest periods.[1](https://www.nature.com/articles/nrc1369) There is no universally accepted definition of a metronomic dose; dose fractions vary by drug and regimen, and the minimum biologically effective dose has been proposed as an alternative dosing parameter rather than part of the definition.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) • [3](https://doi.org/10.3390/cancers15092471) The approach was originally framed as a way of targeting the tumor vasculature rather than the tumor cells themselves, and it has since evolved from salvage treatment into adjuvant and maintenance therapy in selected settings.[1](https://www.nature.com/articles/nrc1369) • [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/)
| Key fact | Detail |
|---|---|
| Definition | Chronic, frequent, low-dose chemotherapy with no prolonged drug-free breaks[1](https://www.nature.com/articles/nrc1369) • [3](https://doi.org/10.3390/cancers15092471) |
| Term coined | "Metronomic", Hanahan, Bergers, and Bergsland, Journal of Clinical Investigation commentary, 2000[4](https://doi.org/10.1172/jci9872) |
| Main drugs | Oral cyclophosphamide, methotrexate, capecitabine, vinorelbine, tegafur-uracil[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) |
| Breast cancer activity | Pooled ORR 34.1% and clinical benefit rate 55.6% across 22 trials (1,360 patients)[5](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693) |
| Toxicity | Pooled grade 3/4 adverse events 29.5%; significantly less vomiting and alopecia than standard dosing[5](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693) • [6](https://mastology.org/journal/article/view/1170) |
| Cost | Metronomic capecitabine about $37–75 per 28 days in the US, versus $6,264 per month for abemaciclib[7](https://www.ovid.com/jnls/cco/fulltext/10.21037/cco-2025-aw-129~the-phase-iii-mecca-study-on-metronomic-chemo-endocrine) |
| Key limitation | No validated biomarkers or consensus optimal dose; published series heterogeneous[8](https://link.springer.com/article/10.1007/s00280-013-2125-x) • [9](https://www.sciencedirect.com/science/article/abs/pii/S0304383516307662) |
## How it works
The founding rationale is anti-angiogenic: frequent low-dose dosing is directed at the proliferating endothelial cells of the tumor neovasculature rather than at tumor cells, several cytotoxic drugs showing antiangiogenic properties when given this way.[1](https://www.nature.com/articles/nrc1369) • [8](https://link.springer.com/article/10.1007/s00280-013-2125-x) Because endothelial cells are genetically stable, this target was proposed as a way to circumvent acquired drug resistance in the tumor cell population.[10](https://doi.org/10.1002/bies.950130106) • [11](https://www.nature.com/articles/nrclinonc.2010.82)
Some metronomic regimens induce sustained suppression of circulating endothelial [progenitor cells](https://www.edgepedia.org/progenitor-cell) (CEPs) and raise levels of thrombospondin 1, an endogenous angiogenesis inhibitor that binds [CD36](https://www.edgepedia.org/cd36) receptors on endothelial cells and induces their apoptosis; in mice, MTD cyclophosphamide mobilized CEPs after each cycle while metronomic cyclophosphamide decreased CEP numbers and viability.[1](https://www.nature.com/articles/nrc1369) • [12](https://aacrjournals.org/cancerres/article/63/15/4342/510313/Maximum-Tolerable-Dose-and-Low-Dose-Metronomic) • [13](https://doi.org/10.1073/pnas.2135406100)
Metronomic chemotherapy is not purely antiangiogenic. It decreases regulatory T-cell populations and promotes antitumor immunity through dendritic-cell maturation and increased cytotoxic T cells, and it may induce tumor dormancy; in pediatric oncology, proposed mechanisms additionally include direct cytotoxicity to cancer stem cells.[14](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1369597/full) • [11](https://www.nature.com/articles/nrclinonc.2010.82) • [15](https://pmc.ncbi.nlm.nih.gov/articles/PMC9657890/)
## How it is done
The primary agents are cyclophosphamide, methotrexate, vinorelbine, tegafur-uracil, and capecitabine.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) In the classic cyclophosphamide–methotrexate (CM) regimen, cyclophosphamide is given at 50 mg/day plus methotrexate 2.5 mg twice per day on days 1 and 2 of each week, without breaks.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) [Capecitabine](https://www.edgepedia.org/capecitabine) schedules include 500 mg three times daily continuously (used in the MECCA trial with an aromatase inhibitor), 650 mg/m² twice daily for one year in the adjuvant setting, and a CX combination of capecitabine 828 mg/m² twice daily with cyclophosphamide 33 mg/m² twice daily on days 1–14 of each 3-week cycle.[16](https://ascopubs.org/doi/10.1200/JCO.24.00938) • [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/)
Metronomic chemotherapy is used both as monotherapy and in combination. Combinations include anti-angiogenic antibodies against VEGF or VEGFR-2, which increase metronomic efficacy; endocrine therapy with aromatase inhibitors; corticosteroids, which were combined with cyclophosphamide in 63.3% of prostate-cancer regimens; and immune checkpoint inhibitors.[1](https://www.nature.com/articles/nrc1369) • [16](https://ascopubs.org/doi/10.1200/JCO.24.00938) • [17](https://www.mdpi.com/2077-0383/11/10/2783)
## Origin
The conceptual precursor was [Robert S. Kerbel](https://www.edgepedia.org/robert-s-kerbel)'s 1991 BioEssays commentary, which outlined treating drug-resistant tumors through chemotherapy effects on dividing endothelial cells of the genetically stable neovasculature.[10](https://doi.org/10.1002/bies.950130106) In 2000, two preclinical demonstrations appeared in the Journal of Clinical Investigation. Giannoula Klement, Robert S. Kerbel and colleagues showed that continuous low-dose vinblastine combined with a VEGF receptor-2 antibody induced sustained tumor regression without overt toxicity.[18](https://doi.org/10.1172/jci8829) A parallel experimental study, distinct from the Hanahan commentary, found that metronomic cyclophosphamide, especially with the angiogenesis inhibitor TNP-470, eradicated aggressive drug-resistant tumors in 32 of 38 tumor-bearing mice, whereas conventional MTD regimens only modestly delayed growth.[4](https://doi.org/10.1172/jci9872) The term "metronomic" itself was introduced in a 2000 Journal of Clinical Investigation commentary by [Douglas Hanahan](https://www.edgepedia.org/douglas-hanahan), Gabriele Bergers, and Emily Bergsland.[4](https://doi.org/10.1172/jci9872)
The first clinical trial was reported by [M. Colleoni](https://www.edgepedia.org/marco-colleoni) and colleagues in 2002: low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer, which also correlated antitumor activity with vascular endothelial growth factor levels.[19](https://doi.org/10.1093/annonc/mdf013) In 2003, L. Michael Glode, Robert Kerbel and colleagues described metronomic cyclophosphamide and dexamethasone for prostate carcinoma.[20](https://doi.org/10.1002/cncr.11713) The field has since shifted from salvage treatment toward adjuvant maintenance use following several phase III trials.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/)
## Variants
Several named schedules and concepts exist. The CM regimen (cyclophosphamide 50 mg/day plus weekly pulsed methotrexate) is the schedule with the most accumulated clinical data.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) • [14](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1369597/full) The chemo-switch regimen, described by Kristian Pietras and Douglas Hanahan in 2005, combines metronomic and MTD dosing in one multitargeted schedule and produced objective responses and survival benefit in a mouse model.[21](https://doi.org/10.1200/jco.2005.07.093) MEDIC (medium-dose intermittent chemotherapy) uses cyclophosphamide at 140 mg/kg every 6 days in murine models, a dose between daily low-dose and MTD, chosen for immunogenic rather than antiangiogenic effect.[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC9657890/) Metronomics refers to the combination of metronomic chemotherapy with drug repurposing.[22](https://doi.org/10.1016/j.trecan.2020.05.007)
## Applications
**Breast cancer**: a meta-analysis of 22 trials (1,360 metastatic breast cancer patients) found a pooled objective response rate of 34.1% (95% CI 27.4–41.5) and clinical benefit rate of 55.6% (95% CI 49.2–61.9).[5](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693) In the adjuvant setting, the SYSUCC001 phase 3 trial showed that one year of metronomic capecitabine (650 mg/m² twice daily) improved 5-year disease-free survival in early-stage triple-negative breast cancer from 73.0% to 82.8% (p = 0.03).[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) The phase III MECCA trial (263 patients) found that metronomic capecitabine 500 mg three times daily plus an aromatase inhibitor extended median progression-free survival to 20.9 months versus 11.9 months with the aromatase inhibitor alone (HR 0.58, P = .0001), median overall survival was not reached with the combination versus 45.1 months with the aromatase inhibitor alone (HR 0.58 [95% CI, 0.37 to 0.93]; P = .022).[16](https://ascopubs.org/doi/10.1200/JCO.24.00938) Against this, a 2026 reconstructed individual patient data meta-analysis of four randomized trials (436 patients, HER2-negative metastatic disease) found metronomic dosing significantly reduced progression-free survival (HR 1.22, 95% CI 1.01–1.49) and overall survival (HR 1.38, 95% CI 1.08–1.76) compared with standard fixed-dose chemotherapy, which the authors concluded remains the recommended standard.[6](https://mastology.org/journal/article/view/1170)
**Nasopharyngeal carcinoma** has positive phase III data: adjuvant metronomic capecitabine improved failure-free survival in high-risk locoregionally advanced disease (85.3% vs 75.7%, p = 0.002), and metronomic tegafur-uracil after radiotherapy improved 5-year overall survival (71.6% vs 28.7%, p < 0.001).[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/)
**Prostate cancer** has no phase III trial documenting benefit; across 30 studies (973 patients), the mean clinical benefit rate was 56.8 ± 24.5%, and in one retrospective comparison MTD docetaxel gave a higher PSA response rate (46.7% vs 12%) but similar mean overall survival.[17](https://www.mdpi.com/2077-0383/11/10/2783)
**Pediatric oncology** uses metronomic schedules mostly for adjuvant, palliative, and maintenance purposes, with practical advantages of low toxicity, oral home-based administration, avoidance of central venous access, and reduced economic burden.[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC9657890/) • [23](https://doi.org/10.1016/s1470-2045%2819%2930617-5)
**Combinations with immunotherapy** are an active area. A phase III randomized trial found that adding low-dose nivolumab to metronomic chemotherapy increased one-year overall survival from 16.3% to 43.4%.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) In the TONIC trial, the overall response rate with short-term induction before nivolumab in metastatic triple-negative breast cancer was 20%, but the cyclophosphamide induction arm achieved only 8%, with doxorubicin induction at 35%.[3](https://doi.org/10.3390/cancers15092471)
Metronomic schedules are less toxic than MTD chemotherapy, with satisfactory results reported in breast and prostate cancer and pediatric sarcomas at minimal toxicity.[8](https://link.springer.com/article/10.1007/s00280-013-2125-x) The pooled grade 3/4 adverse event rate across metronomic breast cancer trials was 29.5% (95% CI 21.1–39.5).[5](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693) In the randomized IPD meta-analysis, metronomic dosing significantly reduced vomiting (OR 0.28) and alopecia (OR 0.16), with no significant differences in diarrhea, anemia, neutropenia, or hand-foot syndrome.[6](https://mastology.org/journal/article/view/1170) Metronomic schedules are not toxicity-free, but they are inexpensive: 28 days of metronomic capecitabine costs about $37–75 in the US, versus $6,264 per month for abemaciclib and $10,950 for ribociclib.[7](https://www.ovid.com/jnls/cco/fulltext/10.21037/cco-2025-aw-129~the-phase-iii-mecca-study-on-metronomic-chemo-endocrine)
## Limitations and alternatives
The published metronomic series are very heterogeneous and often retrospective, with only a few randomized trials, which prevents definitive conclusions across tumor types.[8](https://link.springer.com/article/10.1007/s00280-013-2125-x) The concept also lacks a clear, universally accepted definition, and biomarkers are needed to establish the optimal metronomic dose; viable circulating endothelial progenitor cells have been investigated as a biomarker of antiangiogenic activity, and the optimal biological dose has been proposed as a better dosing parameter than the MTD.[9](https://www.sciencedirect.com/science/article/abs/pii/S0304383516307662) • [3](https://doi.org/10.3390/cancers15092471)
Tumors can escape continuous therapy. In PC-3 prostate xenografts, daily continuous cyclophosphamide produced stable disease lasting about 6 to 8 weeks followed by rapid progression despite continued treatment.[24](https://aacrjournals.org/cancerres/article/65/16/7045/518144/Low-dose-Metronomic-Combined-with-Intermittent)
Against standard chemotherapy, the picture is mixed. In a bevacizumab-based phase III randomized comparison in metastatic breast cancer, metronomic and standard schedules showed no significant differences in response rate (50% vs 58%), progression-free survival (8.5 vs 10.3 months), or serious adverse events (24% vs 25%).[5](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693) The 2026 IPD meta-analysis, however, found standard fixed-dose chemotherapy superior for progression-free and overall survival in HER2-negative metastatic disease.[6](https://mastology.org/journal/article/view/1170) Some combinations have failed outright: a phase III trial of adjuvant metronomic methotrexate and celecoxib in head and neck cancer did not improve progression-free or overall survival, and metronomic vinorelbine plus atezolizumab in advanced NSCLC showed no clinical benefit in efficacy or safety.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/) • [3](https://doi.org/10.3390/cancers15092471) Guideline support is selective: the 2017 International Consensus Guidelines for Advanced Breast Cancer affirmed, with 88% panelist agreement, that metronomic chemotherapy is a reasonable treatment for patients who do not need rapid tumor shrinkage, particularly the low-dose oral cyclophosphamide and [methotrexate regimen](https://www.edgepedia.org/methotrexate-regimen).[14](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1369597/full)
## References
1. [Kerbel & Kamen, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer 4:423–436 (2004)](https://www.nature.com/articles/nrc1369)
2. [Metronomic chemotherapy in cancer treatment: new wine in an old bottle (2024 review)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209710/)
3. [Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors (Cancers, 2023)](https://doi.org/10.3390/cancers15092471)
4. [Douglas Hanahan, Gabriele Bergers, Emily Bergsland (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation.](https://doi.org/10.1172/jci9872)
5. [The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis (PLOS One)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0173693)
6. [Metronomic versus standard fixed dosing chemotherapy in HER2-negative metastatic breast cancer: a reconstructed individual patient data meta-analysis (Mastology, 2026)](https://mastology.org/journal/article/view/1170)
7. [The phase III MECCA study on metronomic chemo-endocrine therapy (Chinese Clinical Oncology, 2025)](https://www.ovid.com/jnls/cco/fulltext/10.21037/cco-2025-aw-129~the-phase-iii-mecca-study-on-metronomic-chemo-endocrine)
8. [Metronomic chemotherapy for cancer treatment: a decade of clinical studies, Cancer Chemotherapy and Pharmacology (2014)](https://link.springer.com/article/10.1007/s00280-013-2125-x)
9. [Mini-review Metronomic chemotherapy: A relook at its basis and rationale (Cancer Letters)](https://www.sciencedirect.com/science/article/abs/pii/S0304383516307662)
10. [Robert S. Kerbel (1991). Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents. BioEssays.](https://doi.org/10.1002/bies.950130106)
11. [Metronomic chemotherapy: new rationale for new directions, Nat Rev Clin Oncol (2011)](https://www.nature.com/articles/nrclinonc.2010.82)
12. [Bertolini et al., Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells, Cancer Res 63:4342–4346 (2003)](https://aacrjournals.org/cancerres/article/63/15/4342/510313/Maximum-Tolerable-Dose-and-Low-Dose-Metronomic)
13. [Guido Bocci and colleagues (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Sciences.](https://doi.org/10.1073/pnas.2135406100)
14. [Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy (Frontiers in Cell and Developmental Biology, 2024)](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1369597/full)
15. [Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies](https://pmc.ncbi.nlm.nih.gov/articles/PMC9657890/)
16. [Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in HR+/HER2− Metastatic Breast Cancer: The Phase III MECCA Trial (Journal of Clinical Oncology)](https://ascopubs.org/doi/10.1200/JCO.24.00938)
17. [Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review (J Clin Med)](https://www.mdpi.com/2077-0383/11/10/2783)
18. [Giannoula Klement and colleagues (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation.](https://doi.org/10.1172/jci8829)
19. [M. Colleoni and colleagues (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Annals of Oncology.](https://doi.org/10.1093/annonc/mdf013)
20. [L. Michael Glode and colleagues (2003). Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer.](https://doi.org/10.1002/cncr.11713)
21. [Kristian Pietras, Douglas Hanahan (2004). A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2005.07.093)
22. [Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All (Trends in Cancer, 2020)](https://doi.org/10.1016/j.trecan.2020.05.007)
23. [Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial (The Lancet Oncology, 2019)](https://doi.org/10.1016/s1470-2045%2819%2930617-5)
24. [Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy | Cancer Research](https://aacrjournals.org/cancerres/article/65/16/7045/518144/Low-dose-Metronomic-Combined-with-Intermittent)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Chemotherapy strategy and timing*
*Initially written Sep 29, 2026 · Edited: Oct 15, 2026; Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license